Daniel Stockholm

Inserm — France

Immunology and Microbiology · Life Sciences

25h-index2.4kcitations87works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammation biomarkers and pathways(18), Muscle Physiology and Disorders(17), Autoimmune and Inflammatory Disorders Research(14), Virus-based gene therapy research(12), Single-cell and spatial transcriptomics(11)

Publications87 total

MyoSOTHES : un capteur de lésions musculaires dans la pathologie numérique. Application de l’intelligence artificielle pour quantifier les caractéristiques myopathologiques dans la Calpainopathie (LGMDR1)
Morphologie·2025
Lysosomal damage is a therapeutic target in Duchenne muscular dystrophy
Science Advances·2025· 5 citedOpen Access
Advanced Imaging and Cytometric Techniques to Characterize Lipid Accumulation in Wolman Disease
Cytometry Part A·2025Open Access
Novel cytometry-based characterization of lysosomal storage disease affected patient's cells
2025Open Access
Targeting lysosomal damage is a new therapeutic perspective for Duchenne Muscular Dystrophy
2025Open Access
Transcriptomic analysis reinforces the implication of spatacsin in neuroinflammation and neurodevelopment
Scientific Reports·2025· 8 citedOpen Access
Figure S6 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Figure S4 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Data from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Figure S9 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Supplementary Table S8 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Figure S5 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Figure S3 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Figure S7 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Supplementary Tables S1 to S7 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Supplementary Video S1 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Supplementary Video S2 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Figure S8 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Figure S10 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024Open Access
Supplementary Table S9 from TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma
2024· 1 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Andràs Páldi(14), Isabelle Richard(12), Guillaume Corre(9), Jérémie Cosette(8), Alice Moussy(7), Olivier Danos(6), Carinne Roudaut(5), Nathalie Bourg(5), Anne Galy(5), J. Beckmann(4), Sylvie Marchand(4), Marc Bartoli(4), Romuald Parmentier(4), Olivier Gandrillon(4), Thi My Anh Neildez‐Nguyen(4), Muriel Hérasse(3), Mathieu Taveau(3), Julien Picot(3), Michèle Malassis-Séris(3), Alain Fischer(3)